The EV-HIV Assay, a Point-of-Care Lateral Flow Immunoassay to Accurately Identify HIV Infection from Blood-Based Extracellular Vesicles

EV-HIV 检测是一种即时横向流动免疫检测，可通过血液细胞外囊泡准确识别 HIV 感染

• 批准号: 10927088
• 负责人: KIMBERLY LUKE
• 金额: $ 30.62万
• 依托单位: INTUITIVE BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10927088
• 关键词: Address; Biological Assay; Blood; Contracts; Development; Diagnostic; Diagnostic tests; Goals; HIV; HIV Infections; Human immunodeficiency virus test; Immunoassay; Laboratories; Lateral; Nucleic Acids; Sensitivity and Specificity; Sepsis; Serology; Testing; Vaccines; clinical practice; extracellular vesicles; next generation; point of care; programs; self testing; seropositive

Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a blood-based, lateral flow HIV diagnostic test that can be employed as point-of-care and as well as for self-testing to differentiate between HIV infection from (VISP).

开发区分HIV感染与疫苗诱导血清阳性的诊断方法：该项目的总体目标是支持开发新的血清学和核酸检测方法，这些方法可以识别HIV感染，同时避免由于疫苗诱导血清阳性（VISP）而导致的假阳性结果，具有高灵敏度和特异性。应开发这些下一代检测试剂盒，以解决HIV检测的一种或所有应用/适应症，即：（1）基于实验室的检测;（2）护理点和临床实践;以及（3）自我检测。该合同旨在开发一种基于血液的横向流动艾滋病毒诊断测试，可用作护理点以及自我测试，以区分艾滋病毒感染（VISP）。